Castinetti Frederic, Nagai Mariko, Morange Isabelle, Dufour Henry, Caron Philippe, Chanson Philippe, Cortet-Rudelli Christine, Kuhn Jean-Marc, Conte-Devolx Bernard, Regis Jean, Brue Thierry
Service d'Endocrinologie, Diabète, et Maladies Métaboliques, et Centre de Reference des Maladies Rares d'Origine Hypophysaires, Hôpital de la Timone, F-13385 Marseille, France.
J Clin Endocrinol Metab. 2009 Sep;94(9):3400-7. doi: 10.1210/jc.2008-2772. Epub 2009 Jun 9.
To date, no study reported long-term follow-up results of gamma knife stereotactic radiosurgery (SR).
The aim of the study was to determine long-term efficacy and adverse effects of SR in secreting pituitary adenomas.
We conducted a retrospective study of patients treated by SR in the center of Marseille, France, with a follow-up of at least 60 months.
A total of 76 patients were treated by SR for acromegaly (n = 43), Cushing's disease (CD; n = 18), or prolactinoma (n = 15) as a primary (n = 27) or adjunctive postsurgical treatment (n = 49).
After withdrawal of antisecretory drugs, patients were considered in remission if they had mean GH levels below 2 ng/ml and normal IGF-I (acromegaly), normal 24-h urinary free cortisol, and cortisol less than 50 nmol/liter after low-dose dexamethasone test (CD) or two consecutive normal samplings of prolactin levels (prolactinoma).
After a mean follow-up of 96 months, 44.7% of the patients were in remission. Mean time to remission was 42.6 months. Twelve patients presented late remission at least 48 months after SR. Two patients with CD presented late recurrence 72 and 96 months after SR. Forty percent of patients treated primarily with SR were in remission. Target volume and initial hormone levels were significant predictive factors of remission in univariate analysis. Radiation-induced hypopituitarism was observed in 23% patients; in half of them, hypopituitarism was observed after a mean time of 48 to 96 months. Twenty-four patients were followed for more than 120 months; rates of remission and hypopituitarism were similar to the whole cohort.
SR is an effective and safe primary or adjunctive treatment in selected patients with secreting pituitary adenomas.
迄今为止,尚无研究报告伽玛刀立体定向放射外科手术(SR)的长期随访结果。
本研究旨在确定SR治疗分泌性垂体腺瘤的长期疗效和不良反应。
我们对法国马赛中心接受SR治疗的患者进行了一项回顾性研究,随访时间至少为60个月。
共有76例患者因肢端肥大症(n = 43)、库欣病(CD;n = 18)或泌乳素瘤(n = 15)接受SR治疗,其中作为主要治疗(n = 27)或辅助性术后治疗(n = 49)。
停用抗分泌药物后,如果患者的平均生长激素(GH)水平低于2 ng/ml且胰岛素样生长因子-I(IGF-I)正常(肢端肥大症)、24小时尿游离皮质醇正常,且低剂量地塞米松试验后皮质醇低于50 nmol/L(CD)或泌乳素水平连续两次正常采样(泌乳素瘤),则认为患者处于缓解状态。
平均随访96个月后,44.7%的患者处于缓解状态。缓解的平均时间为42.6个月。12例患者在SR后至少48个月出现延迟缓解。2例CD患者在SR后72和96个月出现延迟复发。主要接受SR治疗的患者中有40%处于缓解状态。在单因素分析中,靶体积和初始激素水平是缓解的重要预测因素。23%的患者出现放射性垂体功能减退;其中一半患者在平均48至96个月后出现垂体功能减退。24例患者随访超过120个月;缓解率和垂体功能减退率与整个队列相似。
SR是治疗某些分泌性垂体腺瘤患者的一种有效且安全的主要或辅助治疗方法。